Nanoliposomes Co-Encapsulating Photoswitchable Probe and Photosensitizer for Super-Resolution Optical Imaging and Photodynamic Therapy.,Cytometry Part A

当前位置： X-MOL 学术 › Cytom. Part A › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Nanoliposomes Co-Encapsulating Photoswitchable Probe and Photosensitizer for Super-Resolution Optical Imaging and Photodynamic Therapy.
Cytometry Part A ( IF 2.5 ) Pub Date : 2019-07-16 , DOI: 10.1002/cyto.a.23864
Hao Xu ₁ , Bingling Chen ₁ , Wanjun Gong ₁ , Zhigang Yang ₁ , Junle Qu ₁

Affiliation

Photosensitizers (PSs) are ideal cancer theranostic drugs that can be administered as both fluorescence imaging reagents and photodynamic therapy (PDT) drugs. To improve the tumoritropic behavior of PSs, nanoliposomes are presently being considered as optimal PSs carriers. Although nanoliposomal PSs have been utilized in clinical therapy, PSs localization and photosensitive processing in nanoliposomal PSs are rarely observed on nanoscale. Investigating changes in the fine structure of nanoliposomes under photosensitive processing will further our understanding of the photosensitive effect on nanoliposomal PSs. In this study, nanoliposomes co-encapsulating the PSs benzoporphyrin derivative monoacid A (BPD) and the photoswitchable probe Cy5-927 were prepared to realize PDT and nanoscale super-resolution optical imaging. The fine structures of nanoliposomal BPD and Cy5-927 (LBC) were visualized by a home-built stochastic optical reconstruction microscopy (STORM). Our PDT results showed that the photorelease and PDT efficiency of BPD were not decreased by co-encapsulating with Cy5-927 in LBC. Taken together, LBC can be used as a new optical probe and PDT reagent for investigating changes in nanoliposomes fine structure and micro-interaction in the cellular process of PDT. Therefore, our results deepened our understanding of liposome-based PDT for optimizing cancer treatment. © 2019 International Society for Advancement of Cytometry.

中文翻译：

纳米脂质体共封装光开关探针和光敏剂，用于超分辨率光学成像和光动力疗法。

光敏剂（PSs）是理想的癌症治疗药物，可以同时用作荧光成像试剂和光动力疗法（PDT）药物。为了改善PSs的促肿瘤行为，目前认为纳米脂质体是最佳PSs载体。尽管纳米脂质体PS已用于临床治疗中，但很少在纳米级观察到纳米脂质体PS中的PS定位和光敏加工。研究在光敏处理下的纳米脂质体的精细结构的变化将进一步使我们了解对纳米脂质体PSs的光敏作用。在这项研究中，纳米脂质体共包裹PSs苯并卟啉衍生物单酸A（BPD）和光开关探针Cy5-927的制备，以实现PDT和纳米级超分辨率光学成像。纳米脂质体BPD和Cy5-927（LBC）的精细结构通过自制的随机光学重建显微镜（STORM）可视化。我们的PDT结果表明，通过与Cy5-927共包裹在LBC中，不会降低BPD的光释放和PDT效率。综上所述，LBC可用作新的光学探针和PDT试剂，用于研究PDT细胞过程中纳米脂质体精细结构和微相互作用的变化。因此，我们的结果加深了我们对基于脂质体的PDT用于优化癌症治疗的理解。©2019国际细胞计数学会。我们的PDT结果表明，通过与Cy5-927共包裹在LBC中，BPD的光释放和PDT效率不会降低。综上所述，LBC可用作新的光学探针和PDT试剂，用于研究PDT细胞过程中纳米脂质体精细结构和微相互作用的变化。因此，我们的结果加深了我们对基于脂质体的PDT用于优化癌症治疗的理解。©2019国际细胞计数学会。我们的PDT结果表明，通过与Cy5-927共包裹在LBC中，BPD的光释放和PDT效率不会降低。综上所述，LBC可用作新的光学探针和PDT试剂，用于研究PDT细胞过程中纳米脂质体精细结构和微相互作用的变化。因此，我们的结果加深了我们对基于脂质体的PDT用于优化癌症治疗的理解。©2019国际细胞计数学会。

更新日期：2020-01-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11